Gilead Recruits Hepatitis C Specialist McHutchison In Show Of Commitment
This article was originally published in The Pink Sheet Daily
Executive Summary
Appointment of leading hepatitis C expert from Duke to senior VP-liver disease therapeutics reaffirms Gilead's commitment to expanding into hepatitis C.
You may also be interested in...
Gilead Complera Launch Imminent Following FDA Approval
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.
Gilead Complera Launch Imminent Following FDA Approval
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.
Gilead: Near-Term Drug Filings Planned, But HIV Pressure Persists
Gilead expects to file for a new triple combination, Truvada plus Johnson & Johnson's TMC278, later this year, to extend the life of its HIV franchise.